China Pharma Holdings, Inc. (CPHI) Stock Price & Analysis
China Pharma Holdings, Inc. (CPHI) — MoonshotScore 23/100 (Weak band), calculated Nov 18, 2026. Price $0.4384 (-13.00%), as of the Nov 20, 2026 trading session; market cap $18.9M.
Educational signal · not a buy or sell recommendation · How to read this
China Pharma Holdings, Inc. · CPHI · AMEX
China Pharma Holdings, Inc. develops, manufactures, and markets pharmaceutical and biochemical products in China. The company offers a range of generic and branded products, including injectables, tablets, and capsules, targeting hospitals and private retailers.
Price as of Nov 20, 2026
Key Statistics
MoonshotScore v2 · China Pharma Holdings (CPHI)
WeakWhy this rating? Method, drivers & history
Bands for the MoonshotScore: Exceptional 80-100 · Strong 65-79 · Fair 45-64 · Weak below 45.
- Business Quality — Is this a genuinely good business?
- Financial Safety — Could this blow up on me?
- Valuation — Am I paying a fair price?
- Growth Durability — Is the growth real and likely to last?
- Momentum — Is the market already moving on this?
Bottom-tier quality, a strained balance sheet and stalling growth, and it’s expensive on top — broad distress, a capital-preservation call, not a value entry. The score also carries a risk penalty for a bankruptcy-risk score in the distress zone and losses on top of negative retained earnings. Business Quality: Thin; Financial Safety: Strained; Valuation: Full; Growth Durability: Shrinking; Momentum: Slipping.
- Altman Z -0.48 · Piotroski F 3
- ROE -21.0% · ROA -9.4% · current ratio 0.26
Holding back: weak fundamentals, balance-sheet strain, soft growth, weak price trend
What has the MoonshotScore done over time?
| Recorded | Score | Band |
|---|---|---|
| 24 | Weak | |
| 23 | Weak | |
| 23 | Weak | |
| 23 | Weak | |
| 23 | Weak | |
| 23 | Weak |
Daily score refresh is delayed. This is the last recorded calculation.
Calculation uses the most recent completed US trading session. Live price changes do not update the score immediately.
Computed · How the MoonshotScore is computed →
Price & valuation
| Measure | Value | As of |
|---|---|---|
| Latest provided price | $0.4384 | |
| Change on the day | -13.00% | |
| Market capitalisation | $18.9M | — |
| Shares traded on the day | 32.8K |
Price & events
Other perspectives
Council score for China Pharma Holdings (CPHI): perspectives
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
5-Factor Breakdown
Legends Council
6 lenses, 0 current
AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
Read on: Nov 19, 2026 · older than the 27 hours refresh window; not a current reading
Munger's Mindset
Balance Sheet & Valuation · historical
Read on: Nov 19, 2026 · older than the 27 hours refresh window; not a current reading
How to read these bars and different assessments
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.
On Nov 19, 2026, the Munger lens read the price at that time as fairly valued against its own estimate of value.
Readings on this page are from Nov 21, 2026, except a card that shows its own read date.
What is China Pharma Holdings (CPHI), and what does it report?
Short answer
A current FMP business description is unavailable; the listing and provider classification below are the available identity facts. China Pharma Holdings, Inc. (CPHI) is listed on AMEX. It employs 215 people. The market values it at $18.9M.
What are the financial strengths and risks for China Pharma Holdings (CPHI)?
Short answer
What is holding it back is weak fundamentals, balance-sheet strain, soft growth, weak price trend. The distress and quality screens read Altman Z -0.48 · Piotroski F 3. Trailing ratios: ROE -21.0% · ROA -9.4% · current ratio 0.26.
Data-derived red flags
- Listing risk — at $0.4384 the shares sit below the $1.00 minimum bid AMEX requires for continued listing.
- Financial-distress signal — its Altman Z-Score of -0.48 sits in the distress zone (elevated bankruptcy risk).
- Negative return on equity (-21.0%) — the business is not currently generating profit on shareholder capital.
How does China Pharma Holdings compare with its peers?
Short answer
China Pharma Holdings's score ranks 13th of 13 in the bounded comparison shown, against 12 same-model peers. These are company scores, not expected investment returns. The set lists named competitors first, then companies in the same data-provider industry classification closest in market value; that classification is the provider's, not our judgment of business similarity.
| Company | Price | Market value | Score |
|---|---|---|---|
| $1.86 Nov 20, 2026 | $23.3M | 48 5-pillar Nov 18, 2026 | |
| $0.58 Nov 20, 2026 | $82.3M | 35 5-pillar Nov 18, 2026 | |
| $1.71 Nov 20, 2026 | $19.8M | 34 5-pillar Nov 18, 2026 | |
| $3.49 Nov 20, 2026 | $16.6M | 32 5-pillar Nov 18, 2026 | |
| $1.36 Nov 19, 2026 | $6.83M | 32 5-pillar Nov 18, 2026 | |
| $1.52 Nov 19, 2026 | $72.0M | 32 5-pillar Nov 18, 2026 | |
| $0.79 Nov 20, 2026 | $40.8M | 31 5-pillar Nov 18, 2026 | |
| $3.24 Nov 20, 2026 | $42.0M | 30 5-pillar Nov 18, 2026 | |
| $1.29 Nov 20, 2026 | $8.29M | 30 5-pillar Nov 18, 2026 | |
| $5.82 Nov 20, 2026 | $23.1M | 25 5-pillar Nov 18, 2026 | |
| $2.66 Nov 20, 2026 | $28.9M | 25 5-pillar Nov 18, 2026 | |
| $0.57 Nov 19, 2026 | $10.2M | 25 5-pillar Nov 18, 2026 | |
| China Pharma Holdings (CPHI) — this page | $0.4384 | $18.9M | 23 |
Only 5-pillar scores are ranked together. Other models are not directly comparable. Price and score dates are shown separately; market-value dates are unavailable.
The records behind this page
Insider activity
Form 4 records via FMP · Most recent available transactions
- Transactions
- 12
- Identified insiders
- 2
- Purchases
- 0
- Sales
- 0
- Other transactions
- 12
Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent.
Who holds the shares?
Institutional ownership reported through 13F filings.
Tracked investors
Which of the 16 named investors we follow held CPHI in their latest 13F filing, and what they did against the filing before it.
None of the 16 tracked investors reported CPHI in their latest 13F filing.
How to read these figures
These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.
What has been published about China Pharma Holdings (CPHI)?
Common Questions About CPHI
These answers are editorial: 1 of these 9 answers is drawn from the CPHI research dossier (written May 5, 2026 by gemini-2.0-flash); the other 8 are question templates that restate figures shown above. Figures in this section are not part of the source register.
What does the MoonshotScore mean for CPHI?
CPHI carries the MoonshotScore stated above — the Weak band. This is an educational research signal, not a buy or sell recommendation. The number comes from the five-pillar engine (business quality, financial safety, valuation, growth durability, momentum), re-ranked daily against sector peers. China Pharma Holdings, Inc. develops, manufactures, and markets pharmaceutical and biochemical products in China.
Is CPHI a good stock to buy?
Stock Expert AI does not rate CPHI buy, sell or hold. China Pharma Holdings, Inc. carries a MoonshotScore, in the Weak band, a research rating against its peers rather than a forecast. Whether it fits is your call: check what it sells, whether it earns and what the price assumes. This is educational content, not investment advice.
What is the CPHI stock price today?
The last price recorded for China Pharma Holdings, Inc. (CPHI), with its trading session and source, is listed under Price & valuation on this page. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.
What do analysts say about CPHI stock?
Analyst coverage of China Pharma Holdings, Inc. is limited due to its small market capitalization and financial challenges. Key valuation metrics reflect the company's current struggles, including negative profit and gross margins.
What are the key factors to evaluate for CPHI?
China Pharma Holdings, Inc. (CPHI) holds a MoonshotScore in the low range. By investing in research and development and strategic partnerships, CPHI can introduce new products and increase its market share. Not financial advice.
How frequently does CPHI data refresh on this page?
CPHI's price is the last quote we recorded, from the Nov 20, 2026 trading session. Pages are served from a cache, so the copy you are reading can lag that quote. The quote is a provider snapshot, not an exchange feed. Fundamentals follow quarterly filings. V2 is recalculated from the most recent completed US trading session; the score's own date shows its last successful run.
What has driven CPHI's recent stock price performance?
China Pharma Holdings, Inc. (CPHI) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Established presence in the Chinese pharmaceutical market. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider CPHI overvalued or undervalued right now?
China Pharma Holdings, Inc. (CPHI) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
How do I research CPHI before investing?
Before investing in China Pharma Holdings, Inc. (CPHI), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) analyst consensus ratings and price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Machine-generated analysis by Stock Expert AI — model gemini-2.0-flash, generated May 5, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.
Sources: the source register lists the 10 figures on this page — 6 from Financial Modeling Prep (FMP), 3 with no recorded source and 1 from Stock Expert AI's own score and rank. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.
Publication details and research sources
- Published
- Research standards
- Methodology · Editorial policy · Corrections
- Report a number
- sedat@stockexpertai.com